The effects of leflunomide and cyclosporin A on rejection of cardiac allografts in the rat

Scandinavian Journal of Immunology

Volumn 47, Issue 3, 1998, Pages 236-242

  Ostraat O ^a   Qi, Z Q ^a   Tufveson, G ^b   Hedlund, G ^c   Ekberg, H ^a  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Pharmacia & Upjohn AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DEHYDROOROTATE DEHYDROGENASE; INTRALIPID; LEFLUNOMIDE; PROTEIN TYROSINE KINASE; ROQUINIMEX; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERANCE; ENZYME INHIBITION; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SURVIVAL TIME;

ANIMALS; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; RATS; RATS, WISTAR;

EID: 0031955738     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1998.00303.x     Document Type: Article

References (41)

1. Mladenovic V, Domljan Z, Rozman B et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995;38:1595-603.
2. Schorlemmer HU, Seiler FR, Bartlett RR. Prolongation of allogeneic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazol derivative. Transplant Proc 1993;25:763-7.
3. Kuchle CC, Thoenes GH, Langer KH et al. Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transplant Proc 1991;23:1083-6.
4. Williams JW, Xiao F, Foster P et al. Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation 1994;57:1223-31.
5. D'Silva M, Candinas D, Achilleos O et al. The immunomodulatory effect of leflunomide in rat cardiac allotransplantation. Transplantation 1995;60:430-7.
6. He G, McAlister VC, Lee TD et al. Oral leflunomide prevents small bowel allograft rejection in the rat. Transplant Proc 1994;26:1613.
7. Foster PF, Xiao F, Kociss K et al. Leflunomide immunosuppression in rat small intestinal transplantation. Transplant Proc 1994;26:1599-600.
8. Morris RE, Huang X, Cao W et al. Leflunomide (HWA 486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimai thickening after balloon catheter injury. Transplant Proc 1995;27:445-7.
9. Morris RE, Huang X, Gregory CR et al. Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. Transplant Proc 1995;27:2068-9.
10. Swan SK, Crary GS, Guijarro C et al. Immunosuppressive effects of leflunomide in experimental chronic vascular rejection. Transplantation 1995;60:887-90.
11. Xiao F, Chong A, Shen J et al. Pharmacologically induced regression of chronic transplant rejection. Transplantation 1995;60:1065-72.
12. Bartlett RR, Dimitrijevic M, Mattar T et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991;32:10-21.
13. Xu X, Williams JW, Bremer EG et al. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995;270:12398-403.
14. Williamson RA, Yea CM, Robson PA et al. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 1995;270:22467-72.
15. Cherwinski HM, McCarley D, Schatzman R et al. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther 1995;272:460-8.
16. Greene S, Watanabe K, Braatz-Trulson J et al. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995;50:861-7.
17. Cao WW, Kao PN, Chao AC et al. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides. J Heart Lung Transplant 1995;14:1016-30.
18. Cherwinski HM, McCarley D, Schatzman R et al. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther 1995;272:460-8.
19. McChesney LP, Xiao F, Sankary HN et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation 1994;57:1717-22.
20. Lin Y, Sobis H, Vandeputte M et al. Mechanism of leflunomide-induced prevention of xenoantibody formation and xenograft rejection in the hamster to rat heart transplantation model. Transplant Proc 1995;27:305-6.
21. Xiao F, Chong AS, Foster P et al. Leflunomide controls rejection in hamster to rat cardiac xenografts. Transplantation 1994;58:828-34.
22. Kalland T, Aim G, Stalhandshe T. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J Immunol 1985;134:3956-61.
23. Bengtsson M, Simonsson B, Carlsson K et al. Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia. Transplantation 1992;53:882-8.
24. Larsson EL, Joki A, Stalhandske T. Mechanism of action of the new immunomodulator LS2616 on T cell responses. Int J Immunopharmacol 1987;9:425-31.
25. Gonzalo JA, Gonzalez Garcia A, Kalland T et al. Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur J Immunol 1994;24:48-52.
26. Wanders A, Larsson E, Gerdin B et al. Abolition of the effect of cyclosporine on rat cardiac allograft rejection by the new immunomodulator LS-2616 (Linomide). Transplantation 1989;47:216-7.
27. Tufveson G, Gannedahl G, Johnsson C et al. New immunosuppressants: testing and development in animal models and the clinic: with special reference to DSG. Immunol Rev 1993;136:99-109.
28. Gerdin B, Wanders A, Tufveson G. Rat cardiac allografts protected with cyclosporin A are rejected in the presence of LS-2616 (Linomide). Transplant Proc 1989;21:853-5.
29. Gannedahl G, Wanders A, Carlsson M et al. 15-deoxyspergualin effects in rat heart allograft transplantation - relation to dose, timing, and cyclosporine. Transplantation 1993;55:455-6.
30. Bersztel A, Wanders A, Wadstrom J et al. Deoxyspergualin is synergistic with cyclosporin A, but not with FK506 in a rat heart allograft transplantation model. Transplant Proc 1995;27:3547.
31. Östraat Ö, Qi Z, Olausson M et al. Mycophenolate mofetil, azathioprine and cyclophosphamide enhanced efficacy combined with cyclosporine in rat cardiac transplantation. Scand J Immunol 1997;45:343-8.
32. Olausson M, Arvidsson N, Lukes D et al. Inhibition of ATG-induced experimental transplantation tolerance with LS2616. Transplant Proc 1995;27:3541-3.
33. + T cell subsets in low- and high-responder rat strains. J Immunol 1989;143:2828-36.
34. Hall BM. Cells mediating allograft rejection. Transplantation 1991;51:1141-51.
35. Qi Z, Riesbeck K, Östraat Ö et al. Single dose anti-CD4 monoclonal antibody for induction of tolerance to cardiac allograft in high- and low-responder rat strain combinations. Transpl Immunol 1997;5: 204-11.
36. Olausson M, Mjörnstedt L, Lindholm L et al. Non-suture organ grafting to the neck vessels in rats. Acta Chir Scand 1984;150:463-7.
37. Butcher GW, Howard JC. Genetic control of transplant rejection. Transplantation 1982;34:161-6.
38. Stewart R, Butcher G, Herbert J et al. Graft rejection in a congenic panel of rats with de lined immune response genes for MHC class I antigens. I. Rejection of and priming to the RTIAa antigen. Transplantation 1985;40:427-32.
39. Alfrey EJ, Wang X, Lee L et al. Tolerance induced by direct inoculation of donor antigen into the thymus in low and high responder rodents. Transplantation 1995;59:1171-6.
40. McConnell MV, Hall BM. Comparison of CD4 and CD8 T cell reactivity in high-responder and low-responder strain combinations in the rat. Transplant Proc 1989;21:3294-5.
41. Lang R, Wagner H, Heeg K. Differential effects of the immunosuppressive agents cyclosporine and leflunomide in vivo. Leflunomide blocks clonal T cell expansion yet allows production of lymphokines and manifestation of T cell-mediated shock. Transplantation 1995;59:382-9.